Department of Pharmacology, Physiology and Legal and Forensic Medicine, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Department of Human Anatomy and Histology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Int J Mol Sci. 2022 Oct 17;23(20):12424. doi: 10.3390/ijms232012424.
Vitamin D has an immune-modulating effect on respiratory tract infections. For this reason, it has been proposed as part of the treatment in COVID-19. Furthermore, vitamin D deficiency has been associated with worse clinical outcomes of this disease. The aim of this systematic review was to determine whether vitamin D supplementation modifies the disease course. Therefore, eleven studies involving randomised clinical trials are analysed, in which groups of COVID-19 patients with or without vitamin D supplementation as part of the treatment are compared. A control group was treated with best available therapy, and in some of the clinical trials, also with a placebo. According to the outcomes, it seems that patients benefit from receiving a daily or maintained in time vitamin D dose regardless of vitamin D serum levels at the beginning of the trial. The administration of a single vitamin D dose does not seem to have any effect on the health status of these patients. However, the outcomes are heterogeneous and larger clinical trials are necessary.
维生素 D 对呼吸道感染具有免疫调节作用。因此，它已被提议作为 COVID-19 治疗的一部分。此外，维生素 D 缺乏与这种疾病的临床结局恶化有关。本系统评价的目的是确定维生素 D 补充是否会改变疾病进程。因此，分析了十一项涉及随机临床试验的研究，其中比较了 COVID-19 患者在治疗中是否补充维生素 D 作为治疗的一部分。对照组接受最佳可用疗法治疗，在一些临床试验中，也接受安慰剂治疗。根据结果，似乎无论试验开始时血清维生素 D 水平如何，患者都能从每天或及时补充维生素 D 剂量中受益。单次给予维生素 D 剂量似乎对这些患者的健康状况没有影响。然而，结果存在异质性，需要更大规模的临床试验。
